Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center

BACKGROUND: A study was initiated at Roswell Park Comprehensive Cancer Center to capture the real-world experience related to the use of CDK4/6 inhibitors (Ciclibs) for the treatment of metastatic hormone receptor-positive and HER2-negative breast cancer (HR+/HER2-). PATIENTS AND METHODS: A total of...

Descripción completa

Detalles Bibliográficos
Autores principales: Knudsen, Erik S, Schultz, Emily, Hamilton, Deanna, Attwood, Kris, Edge, Stephen, O’Connor, Tracey, Levine, Ellis, Witkiewicz, Agnieszka K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355808/
https://www.ncbi.nlm.nih.gov/pubmed/35666660
http://dx.doi.org/10.1093/oncolo/oyac089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355808/
https://www.ncbi.nlm.nih.gov/pubmed/35666660
http://dx.doi.org/10.1093/oncolo/oyac089

Ejemplares similares